Individualizing Pharmacotherapy. Genetic factors and co-prescribed drugs affecting pharmacotherapy


Dr. M.L. Becker, Erasmus Medisch Centrum Rotterdam
Promotores: Prof. dr. B.H.Ch. Stricker, prof. dr. A.G. Vulto. Co-promotor: Dr. L.E. Visser
 
  • Contents
  • Chapter 1. General introduction
  • Chapter 2. Co-prescribed drugs affecting pharmacotherapy
    • Chapter 2.1. Increasing exposure to drug-drug interactions between 1992 and 2005 in people aged ≥55 years
    • Chapter 2.2. Potential determinants of drug-drug interaction associated dispensing in community pharmacies: a literature review
    • Chapter 2.3. Determinants of potential drug-drug interaction associated dispensing in community pharmacies in the Netherlands
    • Chapter 2.4. Hospitalizations and emergency department visits due to drug-drug interactions: a literature review
  • Chapter 3. Genetic factors affecting pharmacotherapy for type 2 diabetes mellitus
    • Chapter 3.1. Cytochrome P450 2C9 *2 and *3 polymorphisms and the dose and effect of sulfonylurea in type 2 diabetes mellitus
    • Chapter 3.2. Genetic variation in the organic cation transporter 1 is associated with metformin response in patients with type 2 diabetes mellitus
    • Chapter 3.3. Genetic variation in the multidrug and toxin extrusion 1 transporter protein influences the glucose lowering effect of metformin in patients with type 2 diabetes mellitus
    • Chapter 3.4. Interaction between polymorphisms in the OCT1 and MATE1transporter and metformin response
    • Chapter 3.5. Common variation in the NOS1AP gene is associated with reduced glucose-lowering effect and with increased mortality in users of sulfonylurea
  • Chapter 4. Genetic factors affecting cardiovascular pharmacotherapy
    • Chapter 4.1. Common genetic variation in the ABCB1 gene is associated with the cholesterol lowering effect of simvastatin in males
    • Chapter 4.2. Influence of genetic variation in CYP3A4 and ABCB1 on dose decrease or switching during simvastatin and atorvastatin therapy
    • Chapter 4.3. Genetic variation in the NOS1AP gene is associated with the incidence of diabetes mellitus in users of calcium channel blockers
    • Chapter 4.4. A common NOS1AP genetic polymorphism is associated with increased cardiovascular mortality in users of dihydropyridine calcium channel blockers
  • Chapter 5. Genetic factors affecting pharmacotherapy for Parkinson’s disease
    • Chapter 5.1. The OCT1 polymorphism rs622342 A>C is associated with decreased drug response and shorter survival time in Parkinson’s disease
  • Chapter 6. General discussion
  • Chapter 7. Summary